Quantcast Acelity - GRAFTJACKET® Regenerative Tissue Matrix

GRAFTJACKET® Regenerative Tissue Matrix

The information on this page is intended for healthcare professionals. Patient-specific information is available in the “Patients” section of this site. Patients should consult a healthcare professional regarding specific medical conditions and treatments.


Thin, Fenestrated Acellular Human Dermal Matrix Designed for Single Application That Supports Regeneration of Host Tissue

GRAFTJACKET® Regenerative Tissue Matrix (RTM) provides a scaffold for the body’s repair or replacement of damaged or inadequate integumental tissue, such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, or for other homologous uses of human integument. 
Each package of GRAFTJACKET® RTM is intended for use in one patient on a single occasion.
GRAFTJACKET is a trademark of Wright Medical Technology, Inc. and licensed to KCI USA, Inc. Products processed by LifeCell Corporation for KCI.


The dermal matrix that replaces missing dermis with “like-for-like” tissue that is consistent with native dermal tissue, even over exposed bone or tendon.
The matrix has an acellular scaffold and preserved vascular channels that enable repopulation and revascularization by host tissue.

GRAFTJACKET™ Matrix has demonstrated high clinical efficacy as shown in peer-reviewed studies in diabetic foot ulcers.

Single application, in most cases, to treat challenging wounds such as diabetic foot ulcers.

How it Works

  • Overview
  • Mechanism of Action


GRAFTJACKET® RTM is an intact acellular human dermal matrix that has been processed using a patented method designed to minimize damage to the scaffold and thereby reduce potential inflammatory response by the patient.

Mechanism of Action

A Patented Processing Methodology

The patented processing methodology results in an intact, acellular dermal matrix that retains natural biological components and the structural integrity of the complex, three-dimensional dermal matrix including intact vascular channels.
When used as directed, the body recognizes GRAFTJACKET® RTM as itself, and this positive recognition allows the body to initiate its own tissue regeneration process.
The newly regenerated dermal tissue achieves a cellular and vascular status consistent with mature, native dermis.


Materials For Download

Product Information

Indications & Applications

Indications & Applications

Indications for Use

Before use, physicians should review complete risk information and essential prescribing information which can be found in the  Instructions for Use
GRAFTJACKET® RTM for wounds provides a scaffold for the body’s repair or replacement of damaged or inadequate integument tissue, such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, or for other homologous uses of human integument. 
Each package of GRAFTJACKET® RTM is intended for use in one patient on a single occasion.
Step-by-step instructions for the preparation of GRAFTJACKET® RTM convey its ease of use.
  • Measure and trim GRAFTJACKET® RTM to fit the defect and accommodate for wound depth
  • Ensure appropriate sizing to allow for suturing or stapling
  • Dermal side “down” / against the wound bed
Application Techniques:
GRAFTJACKET® RTM is applied using a simple, step-by-step process
  • Ensure that GRAFTJACKET® RTM contacts wound bed completely to enable vascular communication
  • Using skin staples or sutures, circumferentially affix the matrix to the margins of the wound
  • Steri-Strips™ are not recommended
Steri-Strip is a trademark of 3M Company​

Evidence & Outcomes

Randomized controlled trials (RCTs) and retrospective studies support positive clinical outcomes using a single application of GRAFTJACKET® RTM to treat full-thickness lower extremity wounds

Clinical Evidence

Additional summary of evidence and outcomes.

Evidence & Outcomes

Product Evidence and Outcomes

Title Study Type Date Authors
Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study
Randomized Control Trial
Reyzelman et al.
A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds.
Multicenter retrospective study
Winters et al.
The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: A prospective 16-week pilot study
Randomized Control Trial
Brigido et al.
Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: A pilot study
Pilot study
Brigido et al.

Ordering Information

Product Codes

Product Product Code Description
GRAFTJACKET™ Regenerative Tissue Matrix
Thin (0.38)
GRAFTJACKET™ Regenerative Tissue Matrix
Thin (0.38)
Want to learn more? Please call +1 800-275-4524 or click here.

Related Products

Footer Navigation